LINK WILLIAM J PHD 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 16, 2025

Form 4

Period: 2025-06-12

Director

Transactions

Exercise/Conversion
Restricted Stock Units
2025-06-13−3,350→ 0 total
→ Common Stock (3,350 underlying)
Exercise/Conversion
Common Stock
2025-06-13+3,350→ 170,448 total
Award
Stock Option (right to buy)
2025-06-12+4,540→ 4,540 total
Exercise: $40.95Exp: 2035-06-11→ Common Stock (4,540 underlying)
Award
Restricted Stock Units
2025-06-12+2,954→ 2,954 total
→ Common Stock (2,954 underlying)

Holdings

Footnotes (6)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
[F2]The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
[F3]Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
[F4]Each RSU represents a contingent right to receive one share of the Company's common stock.
[F5]RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
[F6]RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Documents

1 file